Merus NV to Present Promising Phase 2 Data for Petosemtamab in Metastatic Colorectal Cancer at Major Oncology Conference

Reuters

11小時前

Merus NV to Present Promising Phase 2 Data for Petosemtamab in Metastatic Colorectal Cancer at Major Oncology Conference

Merus N.V. has announced the upcoming presentation of initial interim data from a phase 2 trial evaluating petosemtamab, a bispecific antibody targeting EGFR and LGR5, in metastatic colorectal cancer (mCRC). The data, which assess petosemtamab in combination with standard chemotherapy in first- and second-line mCRC and as monotherapy in heavily pretreated (third-line and beyond) mCRC, will be presented during a plenary session at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The plenary session is scheduled for Friday, October 24, 2025, from 10:00 to 11:40 a.m. ET. Additionally, Merus will present a poster on the preclinical evaluation of petosemtamab on cancer stem cells during Poster Session B, held on the same day from 12:30 to 4:00 p.m. ET. The abstracts will be available in the conference app starting Wednesday, October 22, 2025, at 12:00 p.m. ET, and full presentations are planned for availability on the Merus website at the start of each session.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merus NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9543421-en) on October 13, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2575837172"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2575837172\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2575837172?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-14 00:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2575837172","market":"us","top_or_hot":-1,"title":"Merus NV to Present Promising Phase 2 Data for Petosemtamab in Metastatic Colorectal Cancer at Major Oncology Conference","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Merus NV to Present Promising Phase 2 Data for Petosemtamab in Metastatic Colorectal Cancer at Major Oncology Conference\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Merus N.V. has announced the upcoming presentation of initial interim data from a phase 2 trial evaluating petosemtamab, a bispecific antibody targeting EGFR and LGR5, in metastatic colorectal cancer (mCRC). The data, which assess petosemtamab in combination with standard chemotherapy in first- and second-line mCRC and as monotherapy in heavily pretreated (third-line and beyond) mCRC, will be presented during a plenary session at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>. The plenary session is scheduled for Friday, October 24, 2025, from 10:00 to 11:40 a.m. ET. Additionally, Merus will present a poster on the preclinical evaluation of petosemtamab on cancer stem cells during Poster Session B, held on the same day from 12:30 to 4:00 p.m. ET. The abstracts will be available in the conference app starting Wednesday, October 22, 2025, at 12:00 p.m. ET, and full presentations are planned for availability on the Merus website at the start of each session.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merus NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9543421-en) on October 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merus NV to Present Promising Phase 2 Data for Petosemtamab in Metastatic Colorectal Cancer at Major Oncology Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerus NV to Present Promising Phase 2 Data for Petosemtamab in Metastatic Colorectal Cancer at Major Oncology Conference\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-10-14 00:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Merus NV to Present Promising Phase 2 Data for Petosemtamab in Metastatic Colorectal Cancer at Major Oncology Conference\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Merus N.V. has announced the upcoming presentation of initial interim data from a phase 2 trial evaluating petosemtamab, a bispecific antibody targeting EGFR and LGR5, in metastatic colorectal cancer (mCRC). The data, which assess petosemtamab in combination with standard chemotherapy in first- and second-line mCRC and as monotherapy in heavily pretreated (third-line and beyond) mCRC, will be presented during a plenary session at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>. The plenary session is scheduled for Friday, October 24, 2025, from 10:00 to 11:40 a.m. ET. Additionally, Merus will present a poster on the preclinical evaluation of petosemtamab on cancer stem cells during Poster Session B, held on the same day from 12:30 to 4:00 p.m. ET. The abstracts will be available in the conference app starting Wednesday, October 22, 2025, at 12:00 p.m. ET, and full presentations are planned for availability on the Merus website at the start of each session.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merus NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9543421-en) on October 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票月供概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251013:nNDLxj2xP:1","article_id":"2575837172","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2575837172","pubTimestamp":1760371227,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Merus N.V. has announced the upcoming presentation of initial interim data from a phase 2 trial evaluating petosemtamab, a bispecific antibody targeting EGFR and LGR5, in metastatic colorectal cancer . The data, which assess petosemtamab in combination with standard chemotherapy in first- and second-line mCRC and as monotherapy in heavily pretreated  mCRC, will be presented during a plenary session at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The plenary session is scheduled for Friday, October 24, 2025, from 10:00 to 11:40 a.m. ET. Additionally, Merus will present a poster on the preclinical evaluation of petosemtamab on cancer stem cells during Poster Session B, held on the same day from 12:30 to 4:00 p.m. ET. The abstracts will be available in the conference app starting Wednesday, October 22, 2025, at 12:00 p.m. ET, and full presentations are planned for availability on the Merus website at the start of each session.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4112":"金融交易所和数据","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","MRUS":"Merus B.V.","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4139":"生物科技","NDAQ":"纳斯达克OMX交易所","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4588":"碎股","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD"},"translate_title":"Merus NV将在主要肿瘤学会议上展示Petosemtamab治疗转移性结直肠癌的有希望的2期数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"MRUS":0.9},"content_text":"Merus NV to Present Promising Phase 2 Data for Petosemtamab in Metastatic Colorectal Cancer at Major Oncology Conference\n    \n\n        Merus N.V. has announced the upcoming presentation of initial interim data from a phase 2 trial evaluating petosemtamab, a bispecific antibody targeting EGFR and LGR5, in metastatic colorectal cancer (mCRC). The data, which assess petosemtamab in combination with standard chemotherapy in first- and second-line mCRC and as monotherapy in heavily pretreated (third-line and beyond) mCRC, will be presented during a plenary session at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The plenary session is scheduled for Friday, October 24, 2025, from 10:00 to 11:40 a.m. ET. Additionally, Merus will present a poster on the preclinical evaluation of petosemtamab on cancer stem cells during Poster Session B, held on the same day from 12:30 to 4:00 p.m. ET. The abstracts will be available in the conference app starting Wednesday, October 22, 2025, at 12:00 p.m. ET, and full presentations are planned for availability on the Merus website at the start of each session.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merus NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9543421-en) on October 13, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"conferences","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}